By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panel is largely bearish on Mineralys' (MLYS) decision to raise funds via equity and debt to buy out Tanabe royalties for lorundrostat. They highlight significant near-term cash burn, heavy leverage, and potential liquidity issues if clinical trials face delays or fail to meet expectations.
Risk: The reliance on expensive, floating-rate debt in a high-rate environment, which could become a liquidity trap if clinical trials face delays.
Opportunity: The potential upside if lorundrostat reaches commercialization and generates significant revenue.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the 10 best AI driven biotech stocks to invest in.
On June 3, Mineralys Therapeutics (NASDAQ:MLYS) shared a major update regarding its blood pressure drug, lorundrostat. The company is repurchasing its potential royalty payments from Tanabe Pharma Corporation. Mineralys is paying $200 million upfront and up to $100 million later based on commercial milestones.
Billion Photos/Shutterstock.com
This moves their total possible future milestone payments to Tanabe up to $265 million, which includes the $100 million in new milestones and $165 million in old milestones, with up to $10 million tied to a second indication. Tanabe will also hand over the intellectual property rights for the drug.
To fund this, Mineralys initiated a $500 million agreement for a senior secured term loan with Pharmakon Advisors that matures in June 2031. They are getting $100 million of that debt immediately at closing, and the rest will come in three separate tranches. The interest rate is based on SOFR with a 3.25% floor, plus a 5.50% annual margin. On top of the loan, Mineralys also priced a separate stock offering to sell about $150 million of its common stock to help cover the upfront costs.
Mineralys Therapeutics Inc. (NASDAQ:MLYS) engages in the development of therapeutics that target illnesses caused by dysregulated aldosterone. It is working on the development of lorundrostat, an aldosterone synthase inhibitor for cardiorenal conditions. These include chronic kidney disease, hypertension, and obstructive sleep apnea.
While we acknowledge the potential of MLYS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
Four leading AI models discuss this article
"The $350M raise to repurchase royalties adds unsustainable leverage and dilution to a single-asset pre-revenue biotech."
MLYS is raising $350M via equity and drawing $100M of a $500M Pharmakon term loan (SOFR + 8.75% effective) to buy out Tanabe royalties for $200M upfront plus milestones. For a pre-revenue biotech whose only asset is lorundrostat in Phase 2/3, this structure adds immediate dilution plus a maturity wall in 2031 that will require either commercial revenue or further raises. The IP transfer is positive but does not change the binary clinical and reimbursement risk. Investors should focus on whether the net royalty savings exceed the cost of capital and dilution over the next five years.
If lorundrostat gains broad approval in hypertension and CKD, eliminating the royalty could preserve several hundred million in future cash flow that more than offsets today's financing costs.
"The deal heavily commodities Mineralys with debt and dilution to back a program whose commercial upside is uncertain, risking balance-sheet strain if lorundrostat underdelivers."
Mineralys is paying upfront and taking on new debt and equity to buy back royalties from Tanabe, effectively consolidating lorundrostat's economics under Mineralys. The cost: $200m upfront, up to $100m in milestones, plus a $500m senior secured loan with a SOFR floor of 3.25% and a 5.50% margin, plus about $150m of new equity. That creates significant near-term cash burn and a heavy leverage load even before any revenue from lorundrostat, which is still in development for cardiorenal diseases. Milestones seem optional and uncertain; if not hit, debt and dilution weigh on profitability. The upside is real only if lorundrostat reaches commercialization; otherwise, this is a financing trap.
If lorundrostat hits milestones and reaches strong commercialization, owning the IP and cash flows could make the deal accretive, turning the debt and equity into a leveraged but productive monetization engine.
"The royalty buyout is a strategic attempt to capture full commercial value, but it significantly increases the company's financial leverage and dilution risk ahead of critical clinical milestones."
Mineralys is aggressively cleaning up its cap table to maximize long-term economics on lorundrostat, but the cost is significant. By trading away ~15% of its market cap via a $150 million equity offering and layering on high-interest debt (SOFR + 5.5%), management is betting the farm on the drug's upcoming Phase 3 readouts. While royalty buyouts are typically a bullish signal of confidence in peak sales, the reliance on expensive, floating-rate debt in a high-rate environment is a liquidity trap if clinical trials face any delays. They are essentially sacrificing current dilution to prevent a massive revenue leak later, assuming they reach commercialization.
The company is essentially using expensive debt and equity to buy back its own future success, which could backfire if the clinical data is merely mediocre rather than blockbuster.
"MLYS has mortgaged 8+ years of cash flow on a single asset in a competitive indication without disclosing Phase 3 readout timing or competitive win probability, making this a binary bet disguised as a strategic milestone."
MLYS is betting the farm on lorundrostat by paying $200M upfront plus $265M in total milestones to own IP outright from Tanabe. The financing structure is aggressive: $500M term loan at SOFR+550bps (floor 8.75%) maturing 2031, plus $150M equity dilution. This makes sense only if Phase 3 data is robust and commercial runway is clear. But the article omits critical details: current trial status, competitive landscape (finerenone already approved for CKD), and whether $265M in milestones are actually achievable given hypertension is crowded. Debt service alone (~$44M annually) is a burn accelerant for a pre-commercial biotech.
If lorundrostat's Phase 3 shows superiority over finerenone and the company achieves even 50% of milestone probability, the $200M upfront looks cheap; royalty buybacks are standard when conviction is high. The real risk isn't the deal structure—it's execution and label scope.
"Claude overstated immediate debt service by assuming full $500M draw when only $100M is taken now."
Claude's $44M annual debt-service estimate assumes the full $500M term loan is drawn immediately, yet Grok notes only $100M is being drawn now. That inflates near-term cash burn by roughly 4x and overstates the liquidity pressure before Phase 3 data. The real risk is the step-up in draws and interest if trials slip, not the headline facility size. Milestone probability also hinges on hypertension data that faces finerenone and other MRAs already on market.
"Near-term debt service should be based on drawn amount, not the total facility; the real pressure comes from the ramp of draws and covenants if trials slip."
Claude's $44M annual debt-service assumes immediate full draw of $500M; Grok correctly notes only $100M is being drawn now, so near-term interest is ~8.75% of $100M (~$8.75M) plus amortization. The bigger risk is the ramp of draws and covenants if trials slip, plus whether milestones are truly achievable. In short, focus on liquidity runway and optionality, not headline loan size.
"The debt facility's restrictive covenants pose a greater existential risk to shareholders than the interest expense itself."
Claude and Grok are fixated on interest expense, but they are missing the real 'poison pill': the debt covenants. A $500M facility for a pre-revenue firm almost certainly includes restrictive clinical milestones and cash-on-hand requirements. If Phase 3 data is anything less than stellar, these covenants will trigger, forcing MLYS to dilute shareholders further at depressed prices to avoid default. The debt isn't just a cost center; it is a ticking time bomb for equity holders.
"Covenant risk is plausible but unverified; the real liquidity question is whether $100M drawn covers the $200M upfront or forces additional draws immediately."
Gemini's covenant risk is real, but the article provides zero detail on actual covenant terms—clinical gates, minimum cash, leverage ratios. We're speculating. More pressing: nobody has asked whether the $100M initial draw covers the $200M upfront payment. If MLYS needs to draw the full $500M to fund the deal, near-term liquidity is worse than Grok's math suggests. That's the actual time bomb, not hypothetical covenant triggers.
The panel is largely bearish on Mineralys' (MLYS) decision to raise funds via equity and debt to buy out Tanabe royalties for lorundrostat. They highlight significant near-term cash burn, heavy leverage, and potential liquidity issues if clinical trials face delays or fail to meet expectations.
The potential upside if lorundrostat reaches commercialization and generates significant revenue.
The reliance on expensive, floating-rate debt in a high-rate environment, which could become a liquidity trap if clinical trials face delays.